Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05297578 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults
A Phase 2 study of Pneumococcal Vaccines, sponsored by Vaxcyte.
- Completed
- Registry status
- Phase 2
- Development phase
- 207
- Enrollment target
- 20
- Study locations
NCT05297578 is a Phase 2 study of Pneumococcal Vaccines that has completed, run by Vaxcyte. The registered enrollment target is 207 participants, below the 1,545-participant average among 5 other Pneumococcal Vaccines trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT05297578, a Phase 2 study of Pneumococcal Vaccines, has completed, sponsored by Vaxcyte.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 207 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 65 years of age and older.
Conditions Studied
Interventions
- BIOLOGICAL Pneumococcal 20-valent Conjugate Vaccine
- BIOLOGICAL 24-Valent Pneumococcal Conjugate Vaccine
Study Locations (20)
Florida
- Accel Research Sites - DeLand Clinical Research Unit - DeLand
- CenExel RCA - Hollywood
- Precision Clinical Research - Sunrise
Georgia
- Meridian Clinical Research - Savannah
- Pivotal Research Solutions - Stonecrest
Kansas
- AMR Newton, formerly Heartland Research Associates - Newton
- AMR Wichita West - Wichita
South Carolina
- Accellacare of Charleston - Mt. Pleasant
- Coastal Carolina Research - North Charleston
Utah
- CenExel JBR Clinical Research - Salt Lake City
- Velocity Clinical Research, Salt Lake City - West Jordan
Alabama
- Accel Research Sites-Birmingham Clinical Research Unit - Birmingham
Illinois
- Healthcare Research Network II, LLC - Flossmoor
Louisiana
- AMR New Orleans - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2022-06-15 |
| Est. Completion | 2023-02-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05297578
The ClinicalTrials.gov registry entry for NCT05297578 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 207 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,545-participant average among 5 other Pneumococcal Vaccines trials with a reported enrollment target (87% lower). The listed sponsor is Vaxcyte, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pneumococcal Vaccines appearing as the primary indexed condition, and to 2 interventions - of which Pneumococcal 20-valent Conjugate Vaccine is the first listed.
NCT05297578 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Georgia, Kansas.
Frequently Asked Questions
What is clinical trial NCT05297578 about?
NCT05297578 is a clinical study titled "Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults". The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 65 years of age and older.
What is the current status of trial NCT05297578?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 207 participants. The study started on 2022-06-15. Estimated completion is 2023-02-15.
What conditions does trial NCT05297578 study?
This clinical trial studies the following conditions: Pneumococcal Vaccines.
What interventions are being tested in trial NCT05297578?
The interventions under investigation include: Pneumococcal 20-valent Conjugate Vaccine (BIOLOGICAL), 24-Valent Pneumococcal Conjugate Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05297578?
This trial is sponsored by Vaxcyte, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05297578 being conducted?
This trial has 20 study locations across Alabama, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumococcal Vaccines
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants
COMPLETED · Phase 2
-
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
RECRUITING · Phase 3
-
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49
RECRUITING · Phase 3
-
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.